Cited by 240Immunotherapy and Immune ResponsesRNA Interference and Gene DeliverySARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Mechanism of action of mRNA-based vaccines

Iavarone, Carlo, O’hagan, Derek T., Yu, Dong, Delahaye, Nicolas F., Ulmer, Jeffrey B.·2017·Expert Review of Vaccines

DOI 10.1080/14760584.2017.1355245

Open this paper in CoChat — free account

Abstract

INTRODUCTION: The present review summarizes the growing body of work defining the mechanisms of action of this exciting new vaccine technology that should allow rational approaches in the design of next generation mRNA vaccines. Areas covered: Bio-distribution of mRNA, localization of antigen production, role of the innate immunity, priming of the adaptive immune response, route of administration and effects of mRNA delivery systems. Expert commentary: In the last few years, the development of RNA vaccines had a fast growth, the rising number of proof will enable rational approaches to improving the effectiveness and safety of this modern class of medicine.

Integrity signals

Registry

Crossref · 10.1080/14760584.2017.1355245

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 2×
“Wolff [2] demonstrated that uptake and expression of exogenous RNA can be achieved without a delivery system.”
Background
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Self-citation
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“Interaction among PRRs and PAMPs triggers the inflammatory response, the link between the innate immunity and the adaptive immunity [43].”
Background
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930

Show all 134 references

Research works printed but not linked: 5

Weissman D., 2015, Expert Vacc Rev
Vormehr M, 2015, J Immunol Res, 595363, 2015
Pepini T, 2017, Induction of an interferon-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design
Thoryk EA, 2016, Vaccines (Basel), 4
Wang WX, 2014, Yao Xue Xue Bao, 49, 1111

Sorted by citations

Items 101–200 of 240

Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
Tsur, S. W., Zaher, E. A., Tsur, M., Kania, K., & Kalinowska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083859 · Cited by 21
Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems
de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., Invenção, M. D. C. V., de Sousa, M. M. G., & de Freitas, A. C. (2022) · Pathogens · doi:10.3390/pathogens11121444 · Cited by 19
Animal Trypanosomiasis: Challenges and Prospects for New Vaccination Strategies
Pereira, S. H., Alves, F. P., & Teixeira, S. M. R. (2024) · Microorganisms · doi:10.3390/microorganisms12122575 · Cited by 18
Building a Better Silver Bullet: Current Status and Perspectives of Non‐Viral Vectors for mRNA Vaccines
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
mRNA extraction from lipid nanoparticles
Malburet, C., Carboni, A., Guinamand, S., Naik, H., & Fertier-Prizzon, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464545 · Cited by 17
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
Kim, D., Robertson, J. S., Excler, J., CONDIT, R. C., Fast, P., Gurwith, M., Pavlakis, G. N., Monath, T. P. C., Smith, J., Wood, D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.017 · Cited by 17
Identification of a Potential mRNA‐based Vaccine Candidate against the SARS‐CoV‐2 Spike Glycoprotein: A Reverse Vaccinology Approach
Durojaye, O. A., Sedzro, D. M., Idris, M. O., Yekeen, A. A., Fadahunsi, A. A., & Alakanse, O. S. (2022) · ChemistrySelect · doi:10.1002/slct.202103903 · Cited by 16
Liquid Chromatography–Mass Spectrometry-Based Qualitative Profiling of mRNA Therapeutic Reagents Using Stable Isotope-Labeled Standards Followed by the Automatic Quantitation Software Ariadne
Nakayama, H., Nobe, Y., Koike, M., & Taoka, M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04323 · Cited by 17
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size
Duncan, M. C., Omondi, F. H., Kinloch, N. N., Lapointe, H. R., Speckmaier, S., Moran-Garcia, N., Lawson, T., DeMarco, M. L., Simons, J. E., Holmes, D. T., et al. (2024) · AIDS · doi:10.1097/qad.0000000000003841 · Cited by 16
Enhancing protective immunity against SARS-CoV-2 with a self-amplifying RNA lipid nanoparticle vaccine
Lin, G., Tang, Y., Fu, Z., Chen, R., Liu, Y., Liu, Z., Kuang, X., Sun, J., Zhao, J., & Zhang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.003 · Cited by 16
Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
Wang, Q., Song, Z., Yang, J., He, Q., Mao, Q., Bai, Y., Liu, J., An, C., Yan, X., Cui, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2059404 · Cited by 16
Advances in mRNA vaccine therapy for breast cancer research
Li, J., Jiang, R., Wang, J., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02542-y · Cited by 16
mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
Ilyichev, A. A., Orlova, L. A., Sharabrin, S. V., & Карпенко, Л. И. (2020) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj20.676 · Cited by 15
COVID-19 vaccines: Frequently asked questions and updated answers
Lefebvre, M., Vignier, N., Pitard, B., Botelho-Nevers, É., Wyplosz, B., Cohen, R., & Épaulard, O. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.02.007 · Cited by 16
Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
Hajissa, K., & Mussa, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1900713 · Cited by 15
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15
SARS-CoV-2 Vaccines and the Skin
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.07.028 · Cited by 14
Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis
Czaja, A. J. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07967-5 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Development of a 3D‐printed single‐use separation chamber for use in mRNA‐based vaccine production with magnetic microparticles
Wommer, L., Meiers, P., Kockler, I., Ulber, R., & Kampeis, P. (2021) · Engineering in Life Sciences · doi:10.1002/elsc.202000120 · Cited by 14
Recent Approaches to mRNA Vaccine Delivery By Lipid-Based Vectors Prepared By Continuous-Flow Microfluidic Devices
Toudeshkchouei, M. G., Tavakoli, A., Mohammadghasemi, H., Karimi, A., Ai, J., Rabiee, M., & Rabiee, N. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0027 · Cited by 15
Current development of Zika virus vaccines with special emphasis on virus-like particle technology
Cimica, V., Galarza, J. M., Rashid, S., & Stedman, T. T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945447 · Cited by 12
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 14
Gene‐encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity
Tursi, N. J., Xu, Z., Kulp, D. W., & Weiner, D. B. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1880 · Cited by 13
Nucleic Acid Armor: Fortifying RNA Therapeutics through Delivery and Targeting Innovations for Immunotherapy
Jiang, Y., Jiang, B., Wang, Z., Li, Y., Cheung, J. C., Yin, B., & Wong, S. H. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168888 · Cited by 15
Development of innovative multi-epitope mRNA vaccine against central nervous system tuberculosis using in silico approaches
Shi, H., Zhu, Y., Shang, K., Tian, T., Yin, Z., Shi, J., He, Y., Ding, J., Wang, Q., & Zhang, F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307877 · Cited by 13
Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic
Al-Ahmady, Z. S., & Ali‐Boucetta, H. (2020) · Frontiers in Nanotechnology · doi:10.3389/fnano.2020.610465 · Cited by 13
Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine
Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 13
RNA research for drug discovery: Recent advances and critical insight
Aja, P. M., Agu, P. C., Ogbu, C. O., Alum, E. U., Fasogbon, I. V., Musyoka, A. M., Ngwueche, W., Egwu, C. O., Tusubira, D., & Ross, K. (2025) · Gene · doi:10.1016/j.gene.2025.149342 · Cited by 17
Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
Ferrari, D., Mangia, A., Spanò, S. M., Zaffarano, L., Viganò, M., Resta, C. D., Locatelli, M., Ciceri, F., & Vecchi, E. D. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0364 · Cited by 11
Research progress of mosquito-borne virus mRNA vaccines
Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
mRNA Vaccine Technology Beyond COVID-19
Oloruntimehin, E. S., Akinyi, F. T., Paul, M., & Ariyo, O. E. (2025) · Vaccines · doi:10.3390/vaccines13060601 · Cited by 13
Construction and immunogenicity of an mRNA vaccine against chikungunya virus
Liu, J., Lu, X., Li, X., Huang, W., Fang, E., Li, W., Liu, X., Liu, M., Li, J., Li, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129118 · Cited by 10
Applications of microfluidics in mRNA vaccine development: A review
Fardoost, A., Karimi, K., Govindaraju, H., Jamali, P., & Javanmard, M. (2024) · Biomicrofluidics · doi:10.1063/5.0228447 · Cited by 12
Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review
Dhanasekaran, P., Karasu, B. T., & Mak, A. (2024) · Rheumatology International · doi:10.1007/s00296-024-05734-x · Cited by 10
Autoimmune‐Like Hepatitis Related to SARS ‐ CoV ‐2 Vaccination: Towards a Clearer Definition
Efe, C., Uzun, S., Matter, M. S., & Beretta‐Piccoli, B. T. (2024) · Liver International · doi:10.1111/liv.16209 · Cited by 10
Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine
Barati, S., Ghoflchi, S., Hosseinzadeh, P., Pouramini, S., Hosseini, H., & Jalili‐Nik, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71187 · Cited by 11
Agglomeration behaviour of magnetic microparticles during separation and recycling processes in mRNA purification
Wommer, L., Soerjawinata, W., Ulber, R., & Kampeis, P. (2021) · Engineering in Life Sciences · doi:10.1002/elsc.202000112 · Cited by 10
Membrane-coated protein nanoparticles for mRNA delivery
Cai, X., Ullah, A., Qian, R., Cui, J., Wu, L. H., & Shen, S. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105427 · Cited by 9
High-Throughput Algorithmic Optimization of In Vitro Transcription for SARS-CoV-2 mRNA Vaccine Production
McMinn, S. E., Miller, D. V., Yur, D., Stone, K., Xu, Y., Vikram, A., Murali, S., Raffaele, J., Holland, D., Wang, S.-C., et al. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00188 · Cited by 9
Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1)
Yahyaei, S., Abdoli, A., Jamali, A., Teimoori, A., Arefian, E., Eftekhari, Z., & Jamur, P. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70093 · Cited by 9
La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe
Reina, J. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.07.009 · Cited by 11
The mRNA Vaccine Heralds a New Era in Vaccinology
Shinde, K., Bendre, S., Kale, N., & Gilda, S. (2022) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2022.00042 · Cited by 9
The new generation of messenger RNA (mRNA) vaccines against influenza
Reina, J. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.07.006 · Cited by 10
The role of mRNA vaccines in infectious diseases: a new era of immunization
Batisani, K. (2025) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-025-00246-3 · Cited by 10
An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodents
Roier, S., Adamo, R., Rosini, R., Pezzicoli, A., Scarselli, M., Petsch, B., Jasny, E., & Rauch, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668937 · Cited by 8
Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective
Blakney, A. K., Top, K. A., Cowling, B. J., Larson, H. J., Shattock, R. J., & Sadarangani, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00512-x · Cited by 11
mRNA vaccines against infectious diseases and future direction
Aleem, M. T., Munir, F., Shakoor, A., & Gao, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112320 · Cited by 10
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 9
An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice
Zhu, J., He, C., Liu, Y. K., Chen, M., Zhang, J., Chen, D., Ni, H., & Wen, J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1472824 · Cited by 7
Schmallenberg virus epidemiology and regional control strategies: diagnostics, vaccines, and vector management
Wang, J., Jia, Q., Xiang, H., Wang, F., Sun, C., Chang, J., Jiang, Z., & Yin, X. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1633030 · Cited by 7
A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research
Zhang, Y., Liu, J., Chang, X., Yang, X., Zhang, X., & Xiao, W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01340-6 · Cited by 7
A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine
Chandarana, C. V., & Tiwari, A. (2023) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871260733231031081921 · Cited by 7
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges
Vosoughi, P., Naghib, S. M., Rahmanian, M., & Mozafari, M. R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266325847241121034100 · Cited by 7
mRNA as a Therapeutics: Understanding mRNA Vaccines
Oğuz, F., & Atmaca, H. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.028 · Cited by 8
Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines
Chentoufi, A. A., Ulmer, J. B., & BenMohamed, L. (2024) · Vaccines · doi:10.3390/vaccines13010030 · Cited by 7
Self-citation
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 7
mRNA Technology in Modern Medicine: Review and Future Prospects
Silva, H. M. (2025) · Clinical and Molecular Epidemiology · doi:10.53964/cme.2025001 · Cited by 4
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines
Banerjee, S., Banerjee, D., Singh, A., & Saharan, V. A. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02247-3 · Cited by 6
Using MicroRNA Arrays as a Tool to Evaluate COVID-19 Vaccine Efficacy
Lin, Y.-P., Hsieh, Y.-S., Cheng, M.-H., Shen, C., Shen, C., & Shen, C. (2022) · Vaccines · doi:10.3390/vaccines10101681 · Cited by 6
Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer
Mongia, P. R., Singh, M. A., Sahu, K. K., Yadav, D. K., Joshi, R., Kaurav, M., Minz, S., Raj, R., & Gupta, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95303-0.00013-7 · Cited by 6
Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines
Xiao, Y., Xu, H., Guo, W. Q., Zhao, Y., Luo, Y., Wang, M., He, Z., Ding, Z., Liu, J., Deng, L., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00017-w · Cited by 6
Vaccines And Advanced Vaccines: -A landscape for advanced vaccine technology against infectious disease ,COVID-19 and tumorPreprint
Cai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
Vaccines in Melanoma
Janes, L. A., Haykal, T., & Angeles, C. V. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.01.004 · Cited by 5
Challenges and Opportunities Used in RNA-Based Therapeutics
Chauhan, P., Tiwari, I., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_10 · Cited by 5
Non-interfacial self-assembly of synthetic protocells
Xu, X., Guan, W., Yu, X., Xu, G., & Wang, C. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00402-w · Cited by 5
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Chen, Z., Liu, Z., Feng, Y., Shi, A., Wu, L., Sang, Y., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1259788 · Cited by 7
Lymphatic Endothelial Cells Produce Chemokines in Response to the Lipid Nanoparticles Used in RNA Vaccines
Liu, Y., Suzuoki, M., Tanaka, H., Sakurai, Y., Hatakeyama, H., & Akita, H. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00689 · Cited by 5
Engineering a novel multi-epitope mRNA vaccine against major bacterial meningitis pathogens: E. coli K1, Group B Streptococcus, Listeria monocytogenes, Neisseria meningitidis, and Streptococcus pneumoniae
Fattahi, N., Khoshnood, S., Omidi, N., & Kalani, B. S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144311 · Cited by 5
Emerging therapeutic modalities against malaria
Chalapareddy, S. K., Sajid, A., Saxena, M., Arora, K., Guha, R., & Arora, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00018-6 · Cited by 5
The therapeutic effect of mRNA vaccines in glioma: a comprehensive review
Afrashteh, F., Seyedpour, S., & Rezaei, N. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2494656 · Cited by 4
DNA Aβ42 immunization via needle-less Jet injection in mice and rabbits as potential immunotherapy for Alzheimer's disease
Lambracht‐Washington, D., Fu, M., Wight‐Carter, M., Riegel, M. S., Hynan, L. S., & Rosenberg, R. N. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120564 · Cited by 4
Characterization of poly(A) and poly(T) tail lengths in plasmid DNA by liquid chromatography high-resolution mass spectrometry
Turihi, N. A., Allouche, D., Quéré, M., Scuiller, M., & Legastelois, I. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05654-6 · Cited by 4
Overview of vaccine adjuvants
Lodaya, R. N., Gregory, S., Amiji, M. M., & O’Hagan, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00003-9 · Cited by 4
Self-citation
Lipid Nanoparticle-Mediated Delivery of Therapeutic and Prophylactic mRNA: Immune Activation by Ionizable Cationic Lipids
Ongun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4
A Computational Search for Peptide Vaccines Using Novel Mathematical Descriptors of Sequences of Emerging Pathogens
Chatterjee, S., Dey, S., Nandy, A., & Basak, S. C. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_108 · Cited by 4
The Design and Prospects of Influenza Virus Vaccines Based on Conserved Epitopes and Adjuvant Optimization
Zhang, M., Bu, J.-W., Wang, Z.-G., & Liu, S. (2025) · Targets · doi:10.3390/targets3020016 · Cited by 3
Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA
Zimmermann, L., & Erbar, S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_5 · Cited by 3
COVID Detection via Nanotechnology: A Promising Field in the Diagnosis and Analysis of Novel Coronavirus Infection
Thakur, N., Shukla, S. K., & Hussain, C. M. (2021) · doi:10.1002/9783527832521.ch4 · Cited by 3
The ability of alphavirus replicases to synthesize non-viral type I interferon-inducing RNAs correlates with viral RNA synthesis and has a diverse impact on virus replication and pathogenicity
Omler, A., Rutmane, A., Mahalingam, S., & Merits, A. (2026) · Journal of Virology · doi:10.1128/jvi.02162-25 · Cited by 2
Safety and heterogeneity of mRNA-based seasonal Influenza vaccines: A systematic review and meta-analysis of randomized controlled trials
Albargy, H. A., & Othman, A. A. (2026) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2026.137 · Cited by 3
RNA-based cancer immunotherapy: Harnessing the power of RNA nanoparticles for melanoma treatment
Liu, X. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156512 · Cited by 2
Perspective Chapter: Next-Generation Vaccines Based on Self-Amplifying RNA
Nafian, F., Nafian, S., Soleymani, G., Pourmanouchehri, Z., Kiyanjam, M., Jalaei, S. B., Jeyroudi, H., & Mohammdi, S. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101467 · Cited by 2
Verzögerte Lokalreaktion mit subkutaner Infiltration nach Impfung mit mRNA-1273 – ein bisher unbeschriebenes Reaktionsmuster eines COVID-Arms
Kofler, L., & Forchhammer, S. (2022) · Der Hautarzt · doi:10.1007/s00105-022-04986-7 · Cited by 2
mRNA, Nanolipid Particles and PEG: A Triad Never Used in Clinical Vaccines is Going to Be Tested on Hundreds of Millions of People
Sousa, A. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.34.005501 · Cited by 2
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien
Monschein, T., Zrzavy, T., Löbermann, M., Winkelmann, A., Berger, T., Rommer, P. S., Hartung, H., & Zettl, U. K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01154-5 · Cited by 2
Recent Update of COVID-19 Vaccines
Jadaan, S. A., & Khan, A. W. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.045 · Cited by 2
SARS-CoV-2 Leading Vaccine Candidates: Progress and Development
Amraiz, D., Fatima, M. T., & Navid, M. T. (2020) · Life and Science · doi:10.37185/lns.1.1.153 · Cited by 2
Interleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice
Li, Y., Liao, Y., Miao, Y., Yu, C., Long, J., Wu, J., Zuo, J., Zhang, Z., Dou, W., Wang, X., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177366 · Cited by 2
Harnessing mRNA vaccines for viral diseases: bottleneck and breakthrough
Mishra, V. K., Ranjan, A., & Mishra, Y. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003212 · Cited by 1
Neoantigen mRNA Cancer Vaccines: How Deep Learning Is Advancing Design and Breaking Barriers
Ismail, S., & Barakat, K. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011567 · Cited by 1
Messenger RNA vaccines for tuberculosis prevention: A narrative review of current research and prospects
Saeed, T. S., Saeed, M. R., Abdullah, M. F., Qureshi, M. S., Saeed, A., Munawar, S., Saifullah, M., & Rana, I. (2025) · World Journal of Pharmacology · doi:10.5497/wjp.v14.i1.110200 · Cited by 1
SARS‐CoV‐2 mRNA Vaccination Leads to Transient Humoral and B Cell Bystander Responses in Adults
Kuijper, L. H., Kummer, L. Y. L., Blanco, L. F., van der Straten, K., Claireaux, M. A. F., Bos, A. V., Dieker, M. C., Jorritsma, T., Duurland, M. C., Steenhuis, M., et al. (2026) · European Journal of Immunology · doi:10.1002/eji.70127 · Cited by 1
mRNA nanotherapeutics for sepsis: immune modulation strategies and translational challenges
Liu, Y., Wang, K., Gao, F., Bai, X., Yang, J., Li, Z., & Wang, Y.-C. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04366-6 · Cited by 2
Genetic engineering approaches to the development of modern therapeutics
Григорьевна, Б. Е., Копейкин, П. М., & Tagaev, A. A. (2020) · Medical academic journal · doi:10.17816/maj34092 · Cited by 1
Effects of Selected Non-biological and Biological Disease-Modifying Anti-rheumatic Drugs, and mRNA Vaccines on Mononuclear Phagocyte System
Dráfi, F., Poništ, S., Sepodes, B. M. N., & Bauerová, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00110-9 · Cited by 1
RNA therapeutics for infectious diseases
Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1
Navigating the horizon of mRNA vaccines: Tracing their evolution, ensuring safety, and unveiling therapeutic potential
Yap, E. C. T. (2023) · International e-Journal of Science Medicine & Education · doi:10.56026/imu.17.3.13 · Cited by 1
COVID-19 and progress in therapeutic approaches: a narrative review
Ilyas, U., Jadoon, S. S., Ahmed, T., Altaf, R., Khan, A., Ahmad, A., Rasool, Y., Masaud, S. M., & Khan, Z. (2024) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1394329 · Cited by 1

Authors: Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B.
Affiliations: GlaxoSmithKline (United States) (US)
Corresponding author: Iavarone, Carlo
ORCID: Yu, Dong
Venue: Expert Review of Vaccines
Publisher: Informa UK Limited
Published: 2017-07-28
Volume: 16
Issue: 9
Pages: 871-881
ISSN: 1476-0584 (ISSN-L)
1744-8395
DOI: 10.1080/14760584.2017.1355245
OpenAlex: W2736048901
Cited by: 234
References: 134
Citations by year: 2026: 13 · 2025: 29 · 2024: 34 · 2023: 33 · 2022: 35 · 2021: 45 · 2020: 26 · 2019: 13 · 2018: 5 · 2017: 1
FWCI: 1.27
Type: journal article
Language: en
Open access: closed
Locations: Expert Review of Vaccines (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Defense Advanced Research Projects Agency
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: mRNA vaccines, vaccine mechanism of action, antigen localization, innate immunity, route of administration, mRNA delivery systems, vaccine design
MeSH terms: Humans, Immunity, Innate, RNA, Messenger, Vaccines, Drug Delivery Systems, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanism of action of mRNA-based vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks